NAVRÁTILOVÁ, Jarmila, Zuzana BUDKOVÁ, Ludmila JIRÁKOVÁ, Kristýna DLABKOVÁ, Jan PREISLER and Jan ŠMARDA. Inhibition of Akt kinase increases cytotoxicity of metaiodobenzylguanidine to neuroblastoma cells. In EACR-OECI Conference Precision Medicine for Cancer. 2015.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Inhibition of Akt kinase increases cytotoxicity of metaiodobenzylguanidine to neuroblastoma cells
Authors NAVRÁTILOVÁ, Jarmila (203 Czech Republic, belonging to the institution), Zuzana BUDKOVÁ (203 Czech Republic, belonging to the institution), Ludmila JIRÁKOVÁ (203 Czech Republic, belonging to the institution), Kristýna DLABKOVÁ (203 Czech Republic, belonging to the institution), Jan PREISLER (203 Czech Republic, belonging to the institution) and Jan ŠMARDA (203 Czech Republic, guarantor, belonging to the institution).
Edition EACR-OECI Conference Precision Medicine for Cancer, 2015.
Other information
Original language English
Type of outcome Presentations at conferences
Field of Study 30200 3.2 Clinical medicine
Country of publisher Luxembourg
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14310/15:00081345
Organization unit Faculty of Science
Keywords in English Akt kinase; metaiodogenzylguanidine; neuroblastoma
Tags AKR
Changed by Changed by: Ing. Andrea Mikešková, učo 137293. Changed: 28/4/2016 15:14.
Abstract
Neuroblastoma is a malignant neuroendocrine tumor, arising from the sympathetic nervous system. It is the most common extracranial solid cancer in childhood. Meta-iodobenzylguanidine (MIBG) and its radioactive form 131I-MIBG are functional analogues of the neurotransmitter norepinephrine that are taken up by 90 to 95% of all neuroblastomas. Whereas most tissues accumulate MIBG by a nonspecific process, cells of the neuroadrenergic tissues and their malignant derivatives exhibit active uptake of the tracer that is mediated by the norepinephrine transporter. Although MIBG is selectively taken up and stored by tumours derived from the neural crest and might stress them in several ways (lipidperoxidation, inhibition of mitochondrial respiration), its toxicity is not very high. Thus, the goal of this study is to increase cytotoxicity of MIBG to neuroblastoma cells. We found that Akt 1/2 kinase inhibitor synergistically increases cytotoxicity of MIBG to neuroblastoma SK-N-Be(2) and SH-SY5Y cells as assessed by combination index analysis. Similar results were obtained for combination of MIBG with L- Buthionine-sulfoximine (BSO), an inhibitor of glutathione synthesis. Cytotoxicity of the MIBG/BSO combination depends on ROS production and diminishes in hypoxia (1% O2). Nevertheless, cytotoxicity of MIBG in combination with Akt1/2 kinase inhibitor is not ROS dependent and is preserved in hypoxic culture conditions. Thus, inhibition of the Akt kinase might be a promising strategy to increase cytotoxicity of MIBG to neuroblastoma.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
EE2.3.20.0183, research and development projectName: Centrum experimentální biomedicíny
GA15-05387S, research and development projectName: Laserově desorpční hmotnostní spektrometrie pro analýzu molekul a nanočástic
Investor: Czech Science Foundation
NT13441, research and development projectName: Exprese proteinů rodiny Myb v adenokarcinomech tlustého střeva a vztah k jejich metastatickému potenciálu
PrintDisplayed: 5/5/2024 14:03